Article Text

Download PDFPDF
Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice

Statistics from


Question: What is the effectiveness and cost of atypical versus typical antipsychotic treatment in people with schizophrenia in real practice?

Population: A total of 8610 adults (mean age 41.5 years, range 16–92 years, 55.4% male) with schizophrenia (International Classification of Diseases (ICD)-10) who were members of four sickness funds met inclusion criteria: complete data on membership available, membership continued throughout study period, aged >16 years and taking prescribed antipsychotics.

Setting: Germany: 2003–2004.

Prognostic factors: Type of antipsychotic prescribed, gender, age and disease severity. Antipsychotic types were high-potency typical antipsychotics 15.8% (n=1356); atypical antipsychotics 35.3% (n=3040); atypical plus high-potency typical antipsychotics 24.7% (n=2126) or atypical with adjuvant therapy 15.6% (n=1341). Drug switching within a drug class was more common for people on typical antipsychotics compared with atypical antipsychotics (55.3% vs 24.9%, p<0.0001). To reduce bias and heterogeneity, analyses were mainly in people who did not switch drugs (atypical 26.5%, n=2284; typical 7%, n=606). Severity of disease was assessed based on days of prior hospitalisation with any diagnosis of schizophrenia.

Outcomes: Rehospitalisation rates; bed days during follow-up; costs of …

View Full Text


  • Sources of funding: Janssen Cilag and National Institute of Health Research.


  • Competing interests None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.